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Abstract
Insomnia and obstructive sleep apnea (OSA) often co-exist, but the nature of their relationship is
unclear. The aims of this study were to compare the prevalence of initial and middle insomnia
between OSA patients and controls from the general population as well as to study the influence
of insomnia on sleepiness and quality of life in OSA patients.
Two groups were compared, untreated OSA patients (n=824) and controls ≥ 40 years from the
general population in Iceland (n=762). All subjects answered the same questionnaires on health
and sleep and OSA patients underwent a sleep study. Altogether, 53% of controls were males
compared to 81% of OSA patients.
Difficulties maintaining sleep (DMS) were more common among men and women with OSA
compared to the general population (52 vs. 31% and 62 vs. 31%, respectively, p<0.0001).
Difficulties initiating sleep (DIS) and DIS+DMS were more common among women with OSA
compared to women without OSA. OSA patients with DMS were sleepier than patients without
DMS (Epworth Sleepiness Scale: 12.2 vs. 10.9, <0.001) while both DMS and DIS were related to
lower quality of life in OSA patients as measured by the Short Form 12 (physical score 39 vs. 42
and mental score 36 vs. 41, p<0.001). DIS and DMS were not related to OSA severity.
Insomnia is common among OSA patients and has a negative influence on quality of life and
sleepiness in this patient group. It is relevant to screen for insomnia among OSA patients and treat
both conditions when they co-occur.
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Introduction
Insomnia is a common and often persistent complaint and includes symptoms such as
difficulties initiating sleep (DIS) and difficulties maintaining sleep (DMS). Studies of
population-based samples have found the prevalence of insomnia to range between 10% and
48%, depending on the definition of insomnia that is used and the population studied (Roth
et al., 2007; Morphy et al., 2007; LeBlanc et al., 2009). Insomnia can be an independent
disorder (primary insomnia) or comorbid with another medical or psychiatric condition.
Primary insomnia is estimated to affect about 25% of all patients suffering from chronic
insomnia (Buysse et al., 1997). Female gender, age, poor self-rated health and snoring have
been associated with increased rates of insomnia symptoms (Klink et al., 1992; Hartz et al.,
2007).
Like insomnia, obstructive sleep apnea (OSA) is a prevalent disorder, often with serious
adverse consequences. OSA is characterized by loud snoring and frequent breathing pauses
during the night due to increased airway resistance which leads to partial (hypopnea) or
complete (apnea) upper airway collapse (Pack and Gislason, 2009). These events lead to
repeated drops in oxygen saturation and, over time, OSA can contribute to impaired daytime
function including excessive daytime sleepiness (EDS), and increased behavioral, metabolic
and cardiovascular morbidity and mortality. Although the most common symptoms of OSA
are loud snoring and daytime sleepiness the condition is often undiagnosed (Young et al.,
2007).
Complaints of insomnia are frequent among OSA patients (Benetó et al., 2009) and in recent
years there has been a growing interest in the co-existence of these disorders. When
insomnia and OSA co-occur, it is likely that the interaction promotes overall greater illness
severity (both in terms of OSA and insomnia) and increases cumulative medical and
psychiatric morbidity (Krakow et al., 2001; Smith et al., 2004; Luyster et al., 2010).
Studies on the relationship between OSA and insomnia have estimated that between 40-60%
of untreated OSA patients are suffering simultaneously from chronic insomnia, a rate which
far exceeds the prevalence in the general population (Krell and Kapur, 2005; Wickwire and
Collop, 2010; Chung, 2005; Subramanian et al., 2010). However, there has been a lack of
studies directly comparing the prevalence of insomnia and its subtypes between untreated
OSA patients and controls from the general population. Since insomnia is prevalent among
OSA patients, it is also of interest whether people from the general population with
symptoms of OSA are at increased risk for insomnia.
The aims of the study were a) to compare the prevalence of difficulties initiating sleep (DIS)
and difficulties maintaining sleep (DMS) in untreated OSA patients vs. controls; b) to
examine whether OSA symptoms are risk factors for insomnia symptoms in a general
population sample from Iceland; c) to examine whether the co-existence of OSA and
insomnia has an additional negative effect on quality of life compared to OSA alone.
Subjects and Methods
Participants
1) Patients diagnosed with OSA in Iceland and referred for treatment with continuous
positive airway pressure (CPAP) to the Landspitali-The National University Hospital of
Iceland from September 2005 - December 2009 were invited to participate in the study.
They are part of the Icelandic Sleep Apnea Cohort (ISAC). Over 90% of the eligible
subjects who were approached agreed to participate. Altogether 824 patients with OSA took
Björnsdóttir et al. Page 2
J Sleep Res. Author manuscript; available in PMC 2013 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
part in this study. Among OSA patients, 81% were males and 19% were females, and the
mean age was 54.4 ± 10.7 years.
2) The controls were 762 individuals aged 40+, randomly sampled from the general
population in Iceland with a response rate of 81% (Benediktsdottir et al., 2010). Among
controls, 53% were males and 47% were females. The controls were on average two years
older (56.4 vs. 54.4) than OSA patients (p<0.001).
Questionnaire and procedure
All participants (both OSA patients and controls) were invited to the outpatient clinic at the
Landspitali-The National University Hospital of Iceland. After written informed consent was
obtained, they answered standardized questionnaires about sleep, daytime sleepiness, health,
lifestyle and quality of life. The protocol was approved by the National Bioethics Committee
of Iceland.
Insomnia
Insomnia was defined using answers to two questions from the Basic Nordic Sleep
Questionnaire: “I have difficulties falling asleep at night” (DIS) and “I wake up often during
the night” (DMS) based on the past month (Partinen and Gislason, 1995). The answers were
rated on a five point scale: never/almost never (1); less than once a week (2); once or twice a
week (3); three to five times a week (4); every day or almost every day of the week (5).
Those who scored ≥ 4 were defined as having insomnia. The prevalence of having both DIS
and DMS at the same time (DIS+DMS) was also explored.
Daytime sleepiness, body mass index and snoring
Daytime sleepiness was evaluated with the Epworth Sleepiness Scale (ESS) (Johns, 1992)
and excessive daytime sleepiness (EDS) was defined as ESS score ≥10. Standardized
methods were used to measure height and weight. BMI was calculated as kg/m2. Habitual
snoring was defined as snoring ≥ 3 nights per week.
Quality of life
Assessment of quality of life was based on the SF-12 questionnaire, a short form of the
SF-36, the most widely used health survey. Two summary component scores can be derived
from the SF-12, both physical (PS) and mental (MS) health summary scores (Ware et al.,
1996). These scores range from 0-100, where a zero score indicates the lowest life quality
and 100 indicates the highest life quality.
Restless legs syndrome
Diagnostic criteria for restless legs syndrome was based on answers from the International
Restless Legs Syndrome Study Group Questionnaire (IRLS) (Benediktsdottir et al., 2010;
Allen et al., 2003). Those who answered the questionnaire as following were regarded as
having RLS; they had a strong urge to move their legs often or very often. The discomfort in
the legs was relieved by moving the legs or walking. The symptoms had to be most
prominent in the evening, at bedtime or no difference of symptoms by the time of day.
Diabetes and hypertension
Participants were defined as having diabetes if they indicated that they had been diagnosed
by a doctor and were using medication for diabetes. Similarly, they were considered to have
hypertension if they had been diagnosed by a doctor and were on antihypertensive
medication.
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Smoking history
Participants were asked about their smoking history; subjects who smoked more than 20
packs of cigarettes in a lifetime or more than one cigarette each day for a year but were not
current smokers were defined as being ex-smokers. Those who had never smoked or smoked
less than 20 packs of cigarettes in their lifetime were defined as being never smokers, while
subjects reporting still to be smoking were classified as current smokers.
Sleep apnea
All OSA subjects had a sleep study while untreated with an Embletta type 3 portable
monitor or an Embla 12 channel system (Embla™; Flaga Inc., Reykjavik, Iceland) recording
the same channels. The sleep recordings were scored in a uniform manner at the Sleep Study
Reading Unit of the University of Pennsylvania. These data were used to calculate an apnea/
hypopnea index (AHI). Events were scored according to the following definitions: a
classification of hypopnea required a ≥30% or greater drop in flow with ≥ 4% oxygen
desaturation or a ≥50% drop in flow for ≥10 seconds with a sudden increase in flow at the
end of the event. A classification of an obstructive apnea required a ≥80% drop in flow for
≥10 seconds. The oxygen desaturation index (ODI) was calculated as the number of falls in
oxygen of >4% per hour of sleep. The minimum SaO2 was defined as the lowest oxygen
saturation reached during the study. Controls did not have a sleep study.
OSA high and low risk controls
Controls were defined as OSA high risk or low risk based on the multivariable apnea index
(MAP) (Maislin et al., 1993). The MAP score is based on self reported presence of apnea
symptoms (snoring or gasping, breathing stops, choking or struggling for breath during
night) as well as BMI and gender. The MAP score ranges between 0 and 1 where subject
who score 0 are the least likely to have sleep apnea. A cut-off of 0.5 has been shown to have
sensitivity of 0.88, specificity of 0.55 and positive predictive value of 0.75 in predicting
OSA (Maislin et al., 1993). This cut-off has however mostly been used on patient groups
and therefore a cut-off of 0.75 in the MAP index was used in this study to divide controls
into OSA high and low risk groups.
Statistical analyses
All statistics were calculated with STATA 11.0 for Windows (Stata Corporation, College
Station, Texas). Differences between the groups of subjects with and without OSA were first
compared using the Chi-square test and unpaired t-test. Multiple logistic regression was then
used to identify which risk factors had an independent association with the outcome
variables. A p value < 0.05 was regarded as statistically significant.
Results
Study population characteristics
Table 1 shows that there were more males among the OSA patients and that they had a
higher BMI, were sleepier and less likely to be never-smokers than controls. In addition,
they had a higher prevalence of hypertension, diabetes and RLS compared to the control
population. DMS was more common among men and women with OSA compared to the
general population. DIS and DIS+DMS were more common among women with OSA
compared to women without OSA (Table 1).
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The prevalence of insomnia
The majority of the OSA patients (57.6%) reported difficulties maintaining sleep compared
to 32% of the controls (p<0.001). The difference in the prevalence of difficulties initiating
sleep (DIS) and DIS+DMS were however not significant between the two groups. DMS was
similarly common among men and women while having DIS and DIS+DMS was more
common among women (p<0.05). Overall, symptoms of insomnia were more frequently
reported by women in both groups (Table 1 and Figures 1 and 2).
Associations with insomnia in controls and OSA patients
Table 2 shows that among the controls, poor mental and physical quality of life,
hypertension and RLS were independent risk factors for both DIS and DMS. In addition, a
high map score was an independent risk factors for DMS.
Among the OSA patients, female gender and smoking were independent risk factors for DIS
while age and RLS were independent risk factors for DMS. Lower mental and physical
qualities of life were associated with both DIS and DMS among controls and OSA patients
(table 3).
DMS was significantly associated with OSA in men when this was tested by combining the
patient population and the general population and adjusting for possible confounders (table
4). No significant association between OSA and DMS was found in women and no
significant independent association between OSA and DIS was found in either gender.
Characteristics of OSA patients and controls with and without insomnia
Among the controls, subjects with DIS and DMS were older, had higher BMI, higher
prevalence of hypertension and RLS and reported poorer mental and physical life qualities
compared to controls without DIS and DMS. In addition, controls with DIS were less sleepy
than controls without DIS (table 5).
Table 6 shows that there was no difference in age, BMI or daytime sleepiness between the
OSA patients with and without DIS. However, the OSA patients with DIS reported poorer
mental and physical quality of life and a higher prevalence of RLS compared to OSA
patients without DIS. The OSA patients with DMS were older, with more daytime
sleepiness, higher prevalence of RLS and poorer quality of life than the OSA patients
without DMS (table 6). When considering the genders separately, the only difference was
that men with DMS were older than men without DMS (54.8 years vs. 51.9 years; p<0.001)
but no significant age difference was found among women. In addition, women with DIS
did not report poorer physical health while that difference remained significant among men
(p<0.001).
The prevalence of DIS and DMS was not related to OSA severity expressed as AHI,
minimum SaO2 or ODI.
OSA high risk and low risk controls
The OSA high risk definition was met by 92 (12.0%) controls with a mean MAP score of
0.81 ±0.05. The low risk controls were 672 (88.0%) individuals with a mean MAP score of
0.33±0.2.
DMS was reported among 39.7% of high risk controls compared to 31.1% of low risk
controls (p=0.135). DIS was reported among 22.9% of high risk controls compared to 13.2%
of low risk controls (p=0.027). Both DIS and DMS were most frequent among subjects with
the highest MAP score (0.75-1.0). Symptoms of DIS are particularly common among
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subjects with MAP score between 0.75-1.0 compared to subjects with a lower MAP score
(p<0.05) (figure 3). High risk controls reported poorer physical life qualities compared to
low risk controls (p<0.001) but the difference in mental life qualities was not significant.
Figure 3. Prevalence (%) of difficulties initiating sleep (DIS) and difficulties maintaining
sleep (DMS) based on multivariable apnea index (MAP).
Discussion
In our study, the majority of the OSA patients (57.6%) had DMS compared to one third of
controls. The prevalence of DIS and DIS+DMS was only significantly higher among women
with OSA compared to women without OSA. This is not surprising since 80% of the OSA
patients in this study were men and DIS is generally more common among women
(Subramanian et al., 2010; Li et al., 2002).
The OSA patients with insomnia reported poorer physical and mental quality of life
compared to patients without insomnia. Furthermore, the OSA patients with DMS were
older and sleepier than other OSA patients. Patients with DIS were not sleepier than patients
without DIS which is consistent with the idea of insomnia as a state of hyper-arousal.
Poor physical and mental health as measured by the SF 12, RLS and hypertension were
significantly related to an increased risk of insomnia in the general population. Overall, 12%
of the general population had a high risk for OSA when using the 0.75 cut-off point in the
MAP index. This is a very high prevalence which might suggest that OSA is often
undiagnosed. Being in high risk for OSA as measured by the MAP was an independent risk
factor for DMS among controls.
Among the OSA patients, female gender, smoking history and poor mental and/or physical
life qualities were independent risk factors for DIS, while age, RLS and poor mental life
qualities were independent risk factors for DMS. It is important to note, however, that poor
quality of life can be the result of insomnia rather than a predictor of the disorder. The
association we have demonstrated does not allow us to distinguish between these
possibilities. Some components of quality of life, such as pain and anxiety, are likely risk
factors for the onset of insomnia while other components such as being inactive and
depressed can be the result of insomnia (LeBlanc et al., 2009; Hartz et al., 2007). As there
was no evaluation of depression and anxiety besides the Short Form 12 in this study the use
of other tools would have been beneficial in order to understand this association better.
One explanation for the high rate of insomnia in patients with OSA is that the apnea may
serve as a precipitating factor for DIS and DMS and may co-occur in such a manner as to
exacerbate these conditions. It is possible that when falling asleep some OSA patients may
be repeatedly disrupted from light sleep by an apnea event causing them not to perceive
sleeping in between the disruptions. These events could recur many times before sleep is
established and as a result the patient experiences long sleep latency. The same pattern could
happen when patients wake up in the middle of the night and are having difficulties falling
back to sleep. Alternatively, apneic events may lead to full awakenings from sleep, but then
the individual is not able to fall back to sleep due to sleep-related anxiety and conditioned
arousal.
Symptoms of insomnia may have a negative effect on CPAP treatment in that it is probably
difficult for those insomnia patients who have DIS to spend a long time awake in order to
adapt properly to the CPAP device. On the other hand, those OSA patients who wake up
frequently because of apneic episodes and complain of difficulty maintaining sleep might
experience more refreshing sleep and adjust favorably to CPAP. It would therefore be
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interesting to study the prevalence of insomnia subtypes among OSA patients before and
after CPAP.
It has been suggested that the best treatment results are obtained when patients are treated
for both disorders separately (Wickwire and Collop, 2010). There is clearly a co-occurrence
of these disorders which could have important clinical implications. Compliance to CPAP
treatment is relatively poor but only around 50% of patients are compliant with treatment
over time (Haynes, 2005). Insomnia could have a negative effect on CPAP compliance and
therefore it could be important to adjust treatment of these conditions when they co-exist in
order to minimize the negative impact on quality of life and avoid a vicious cycle where
these conditions intensify the severity of each other.
Comparing the prevalence of insomnia among studies is often difficult due to the differences
in the definition of insomnia and the different populations studied. Some studies have
reported a similar prevalence of insomnia among sleep apnea patients (Krakow et al., 2001;
Luyster et al., 2010; Krell and Kapur, 2005; Subramanian et al., 2010) as we did here, but
others have found a slightly lower prevalence (Smith et al., 2004; Wickwire and Collop,
2010). However, it is a shared conclusion that symptoms of insomnia are more prevalent
among OSA patients than in the general population. Theoretically, this is surprising since
one of the main symptoms of OSA is daytime sleepiness and therefore one might think that
these patients would be protected against insomnia. The fact that insomnia is so prevalent
among OSA patients strongly hints to a mechanistic link between these conditions.
In our study, there was no relationship between OSA severity and insomnia even though
having OSA was a strong risk factor for DMS. This is surprising and one possible
explanation might be that patients with more severe sleep apnea have greater hypercapnia
because of the severity of their disease, their increased weight and the possible co-
occurrence of obstructive pulmonary disease (COPD). This could mean that they are sleepier
at bedtime and less likely to wake up during the night (Kaw et al., 2009; Witzenblum et al.,
2008). Similar results were found in a recent study (Hagen et al., 2009) which indicated that
even though OSA and insomnia often co-exist, insomnia is still independent of the degree of
OSA. Another study by Kapur and colleagues (2005) suggested that DMS and sleep apnea
severity were independent of each other, but it is clear that prospective studies are needed to
further clarify the issue.
Our study is the first one to look systematically at a high MAP index as an independent risk
factor for insomnia in a general population sample. Having a high MAP index (≥0.75) was a
significant predictor for DMS. This is not surprising given the high prevalence of DMS
among OSA patients. However, having DMS was not more prevalent among high risk
subjects compared to low risk subjects (p=0.135). DIS was on the other hand more prevalent
among those in the high risk group (p=0.027).
The current study has several limitations. The insomnia definition was based on two
questions answered in a self-report, whereas having a more accurate insomnia evaluation
would have been beneficial. Subjects from the general population sample were all aged 40
years or older and therefore results from this study cannot be generalized to younger people.
This study was cross-sectional and therefore we could not assess whether the variables
associated with the presence of insomnia were risk factors or consequences of insomnia.
Lastly, OSA was not objectively assessed in the control group so the prevalence and
associations with insomnia in the general population cannot be accurately determined from
these data.
In summary, we found that OSA and DMS frequently co-exist and patients with both
conditions are older, sleepier and report poorer life qualities than other OSA patients. There
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are a number of clinical implications of these results. First, providers should routinely screen
for the presence of insomnia in OSA patients given that it is associated with greater
impairment in quality of life than OSA alone and the possible negative impact on CPAP
treatment. Assessment of insomnia should take into account the insomnia subtypes among
these patients since different subtypes have different rates, consequences and risk factors.
Providers should consider treating both conditions together when they co-occur in order to
maximize clinical outcomes. This may lead to both direct improvement in symptoms by
reducing the severity of insomnia, and indirectly, by influencing adherence to CPAP
treatment. Further studies are needed to explore whether pharmacologic or cognitive
behavioral treatment of insomnia optimizes outcomes in this population when combined
with CPAP.
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Figure 1.
Prevalence of difficulties initiating sleep (DIS), difficulties maintaining sleep (DMS) and
DIS+DMS among men and women from the general population.
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Figure 2.
Prevalence of difficulties initiating sleep (DIS), difficulties maintaining sleep (DMS) and
DIS+DMS among OSA patients.
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Figure 3.
Prevalence (%) of difficulties initiating sleep (DIS) and difficulties maintaining sleep (DMS)
based on multivariable apnea index (MAP).
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Table 2
Factors associated with DIS and DMS in the general population. The association expressed as adjusted odds
ratio with a 95% confidence interval (OR (95% CI).
DIS
OR (95% CI)*
DMS
(OR 95% CI)*
Smoking history 0.96 (0.69-1.33) 0.98 (0.77-1.24)
RLS 2.69 (1.60-4.53) 2.08 (1.36-3.18)
SF12 MS 0.91 (0.87-0.95) 0.95 (0.92-0.99)
SF12 PS 0.93 (0.90-0.95) 0.97 (0.94-0.99)
Diabetes 0.59 (0.21-1.66) 0.92 (0.44-1.95)
Hypertension 1.21 (0.74-1.96) 1.64 (1.15-2.34)
Map index 1.59(0.59-4.35) 2.13 (1.02-4.43)
*
adjusted for all the variables in the table. RLS (restless leg syndrome), SF12 MS (Short form 12 mental score), SF12 PS (Short form 12 physical
score), MAP (Multivariable apnea index). Significance is marked as bold.
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Table 3
Factors associated with DIS and DMS among OSA patients. The association expressed as adjusted odds ratio
with a 95% confidence interval (OR (95% CI).
DIS
OR (95% CI)*
DMS
(OR 95% CI)*
Age per 10 years 0.89 (0.70-1.10) 1.27 (1.08-1.48)
Female gender 2.43 (1.51-3.91) 0.89 (0.60-1.31)
BMI by 5 units 1.04 (0.86-1.27) 1.14 (0.98-1.32)
Ex smoker 0.97 (0.56-1.68) 1.12 (0.80-1.63)
Current smoker 2.40 (1.35-4.25) 0.96 (0.63-1.47)
Snoring every day 0.64 (0.38-1.07) 1.29 (0.88-1.88)
RLS 1.11 (0.69-1.77) 1.71 (1.18-2.46)
SF12 MS 0.96 (0.94-0.98) 0.98 (0.97-1.00)
SF 12 PS 0.97 (0.95-0.99) 0.98 (0.97-1.00)
Diabetes 1.03 (0.54-2.00) 0.69 (0.42-1.13)
Hypertension 1.12 (0.70-1.78) 1.00 (0.72-1.38)
*
adjusted for all the variables in the table. BMI (body mass index), RLS (restless leg syndrome), SF12 MS (Short form 12 mental score), SF12 PS
(Short form 12 physical score). Significance is marked as bold.
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Table 4
The association between OSA with DIS and DMS in men and women. The association expressed as adjusted
odds ratio with a 95% confidence interval (OR (95% CI)).
DIS
(OR (95% CI)*
DMS
(OR (95% CI)*
Men 0.55 (0.32-1.97) 2.11 (1.52-2.93)
Women 0.60 (0.26-1.23) 1.50 (0.83-2.69)
*
Adjusted for population (patient vs. controls), age, BMI, smoking history, RLS, mental and physical life qualities, hypertension and diabetes.
Significance is marked as bold.
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